News

21/04/15

Strong sales growth in Q1 2015 (up 7.5%) exceeding targets

21/04/15
Strong sales growth in Q1 2015 (up 7.5%) exceeding targets

Positive performance in all geographic regions

Significant growth in the...

[more]
30/03/15
Stallergenes announces the approval in Japan of STG320, the first sublingual immunotherapy tablet for the treatment of house dust mite allergy

STG320 is the first house dust mite immunotherapy tablet ever to obtain a...

[more]

Follow us on :

STALLERGENES, A GLOBAL ALLERGY PLAYER


Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. 

Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.